#Germany #Frankfurt #Zentiva #APONTIS PHARMA

Zentiva's Acquisition of APONTIS PHARMA

Frankfurt, Germany – In a significant development within the pharmaceutical industry, Zentiva AG, a wholly-owned subsidiary of Zentiva Pharma GmbH, has announced it has secured approximately 83.57% of the share capital and 85.27% of the voting rights of APONTIS PHARMA AG through its voluntary public acquisition offer. This announcement came following the completion of the acceptance period on November 21, 2024.

Zentiva’s CEO, Steffen Saltofte, expressed satisfaction with the successful bid, seeing it as a major milestone in the company's mission to expand its reach and enhance its capabilities in delivering high-quality, affordable medications to those in need. He stated, "We are pleased with the success of our public acquisition offer. This milestone is an important step forward in our journey to expand our reach and improve our capability to supply affordable and high-quality medicines to the people who rely on them every day. We look forward to combining our strengths and working together under a unified ownership structure to fulfill our long-term strategy."

As part of the acquisition process, the finalization is still contingent on approval from the foreign direct investment control in Germany, with an anticipated settlement expected to occur either in December 2024 or by the first quarter of 2025.

About Zentiva

Zentiva is a pan-European platform dedicated to developing, manufacturing, and supplying high-quality and affordable medicines to over 100 million people across Europe. With four in-house manufacturing facilities and an extensive network of external manufacturing partners, Zentiva ensures a reliable supply chain. The company’s offerings span critical therapeutic areas, including hemodynamics, diabetes, oncology, respiratory, and CNS. Additionally, Zentiva is focused on expanding its portfolio in self-care solutions. Notably, Zentiva has been experiencing sustainable double-digit growth and has set ambitious five-year growth plans, both organically and inorganically, throughout Europe.

Currently, Zentiva employs nearly 5,000 unique talents united by a shared purpose of providing health and wellbeing for all generations. They prioritize creating a welcoming work environment where everyone feels appreciated and valued, allowing them to contribute to their fullest potential.

For more detailed information about Zentiva, interested parties can visit their official sites at www.zentiva.com or www.zentiva.de.

About APONTIS PHARMA

APONTIS PHARMA is a prominent pharmaceutical company in Germany, specializing in single-pill combinations. These innovative combinations merge two or three active ingredients into a single daily dosage. Research has shown that single-pill therapies significantly enhance therapeutic compliance, thereby improving treatment outcomes and quality of life for patients, while also reducing complications, mortality, and treatment costs. As a result, single-pill combinations are preferred in numerous international treatment guidelines, including those of the EU and Germany.

Since its inception in 2013, APONTIS PHARMA has developed, promoted, and distributed an extensive range of single-pill combinations and other pharmaceutical products, particularly focusing on cardiovascular diseases such as hypertension, lipid disorders, and secondary prevention. For those seeking more information about APONTIS PHARMA, they can be found at www.apontis-pharma.de.

Important Note

This announcement does not constitute an offer to purchase or a request for an offer to sell shares of APONTIS PHARMA or any other securities. The offer is conducted only through the publication of the offer document dated October 24, 2024, and amended on November 19, 2024, and is exclusively subject to the terms and conditions laid out in that document.

Investors and shareholders of APONTIS PHARMA are strongly advised to read the amended offer document and all other relevant materials when available, as they will contain essential information. The amended offer document is published in German and includes a non-binding English translation and can be accessed at www.zentiva-offer.com.

The publication may include statements relating to Zentiva, APONTIS PHARMA, and/or any of their affiliates that are or may be considered "forward-looking statements". These forward-looking statements involve risks and uncertainties and are based on current expectations, assumptions, estimates, and projections. While they do endeavor to provide accurate information, neither Zentiva nor APONTIS PHARMA guarantees that such events will occur or provide future performance predictions. A forward-looking statement refers only to the date of this announcement, and unless required by applicable law, they do not undertake any obligation to update or publicly revise any forward-looking statements as new information becomes available or other events unfold.

Since APONTIS PHARMA's shares are not listed on a regulated market, the offer is not subject to regulation under the WpÜG (German Securities Acquisition and Takeover Act). Therefore, the offer will be executed in accordance with German law as well as specific US securities law provisions.